Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PorA is a major class 1 outer membrane protein of Neisseria meningitidis that functions as a cation-selective porin, facilitating the transport of small hydrophilic molecules across the bacterial outer membrane (UniProt: P0A725). It is a highly immunogenic protein and serves as a primary target for the host's bactericidal antibody response during infection (PubMed: 22939900). Because PorA is highly variable among different strains, it is often delivered via outer membrane vesicles (OMVs), which are naturally occurring blebs of the bacterial membrane that preserve the protein's native conformation and include other surface antigens like PorB, RmpM, Opa, and Opc (PubMed: 15507154). These OMV-based formulations are critical components of vaccines designed to protect against Serogroup B meningococcal disease, for which traditional polysaccharide vaccines are ineffective due to the similarity between the Serogroup B capsule and human neural tissues (CDC: Meningococcal Vaccination). In clinical applications, such as the Bexsero vaccine, the OMV component provides specific protection against strains expressing matching PorA serosubtypes while also providing a synergistic effect with other recombinant antigens (EMA: Bexsero Summary of Product Characteristics). The primary mechanism of action involves the induction of serum bactericidal antibodies that trigger the complement system to lyse the bacteria. Monitoring efficacy typically involves measuring bactericidal titers against specific reference strains using the human serum bactericidal assay (hSBA).
Induction of complement-mediated bactericidal antibody response
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Neisseria meningitidis outer membrane vesicle PorA and associated surface proteins (PorA/OMV).